Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?

Visit https://www.peervoice.com/RYR860 to view the entire programme with slides. After completing “Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?”, participants will be able to: Summarise key findings from published studies evaluating radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC); Discuss optimal sequencing of treatment for patients with mCRPC; and Propose opportunities to optimise the management of patients with mCRPC through effective therapeutic sequencing.